COMMERCIALISATION OF NEW
NANO - TECHNOLOGY FOR CANCER
DIAGNOSIS AND TREATMENT
Cancer metastases ( secondary tumours that have broken away from the primary tumour ) are particularly difficult to detect and treat . Former Flagship 3 Fellow , Dr Yaser Gholami has invented a cancer theranostic kit ( CTK ) with the potential to non - invasively detect , characterise and treat metastatic disease . This invention uses radiolabelled nanoparticles , with a radioisotope that is either a PET tracer ( e . g . Cu or Zr or similar ) or a therapeutic isotope ( e . g . Y or Lu or Cu or similar ). This device can be injected intravenously or locally for imaging and treating cancer metastases . This invention has future clinical translational applications in many areas of cancer imaging and treatment . As a proof - of - concept , it has already been translated into clinical practice for OncoSil micro - particle radionuclide therapy dosimetry of pancreatic cancer . More details on this technology can be found here . Flagship 3 researchers have also initiated a start - up company , RadioDynamic Therapeutics Inc ., with Canadian collaborators around patent PCT / AU2018 / 000247 . The core technology builds on two existing clinical therapies , chemotherapy and X - ray radiation via an engineered liposome delivery system , creates a new treatment option ( X - ray activated chemotherapy ). This innovative nanocarrier design allows the delivery of chemotherapy to be precisely synchronous with radiation and has been applied to the treatment of colorectal and pancreatic cancer . This work has also been published in Nature Communications and can be found here . 64 89 90 177 67
P A G E
6 0
Made with FlippingBook - professional solution for displaying marketing and sales documents online